Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 01, 2022

SELL
$13.13 - $24.52 $102,414 - $191,256
-7,800 Closed
0 $0
Q3 2021

Nov 10, 2021

BUY
$21.01 - $27.64 $8,992 - $11,829
428 Added 5.81%
7,800 $200,000
Q2 2021

Aug 10, 2021

BUY
$23.49 - $35.8 $173,168 - $263,917
7,372 New
7,372 $192,000

Others Institutions Holding ALLO

About Allogene Therapeutics, Inc.


  • Ticker ALLO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 143,807,008
  • Market Cap $326M
  • Description
  • Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...
More about ALLO
Track This Portfolio

Track Agf Investments Inc. Portfolio

Follow Agf Investments Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Agf Investments Inc., based on Form 13F filings with the SEC.

News

Stay updated on Agf Investments Inc. with notifications on news.